This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to develop and validate a new diagnostic tool for obstructive sleep apnea (OSA) called Deep Learning-Enhanced Transmembranous Electromyography (DL-TMEMG). The overarching objective is to create a convenient, point-of-care solution for accurate OSA detection that can be used by any practitioner.
The $615,621 in funding will support a two-phase study. Phase 1 will establish the feasibility of TMEMG to diagnose OSA with good accuracy and optimize the deep learning algorithm. Phase 2 will demonstrate the generalizability and accuracy of DL-TMEMG in a diverse patient population, identify subpopulation differences, and progress regulatory approval. Successful development of this technology is expected to enhance personalized OSA management and improve healthcare accessibility, particularly in underserved areas and for pre-surgical and perinatal patients. The award was granted to Powell Mansfield, Inc. on September 17, 2024 and is set to be completed by September 16, 2025.
Generated 1/28/25, 11:05 AM